SVA [SINOVAC BIOTECH] NT 20-F: (Original Filing)
[]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today ]
SVA [SINOVAC BIOTECH] 6-K: Sinovac to Delay Filing of 2017 Annual Report
[Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today ]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Enters into Amendment to Amalgamation Agreement for
[Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction Under the terms of the Amalgamation Agreement, the Amalgamation Agreement may be terminated by the Company or Parent if the amalgamation of Amalgamation Sub with and into the Company (the “Amalgamation”) has not oc]
BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, April 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on EX-99.1 2 e]
BSPM [Biostar Pharmaceuticals] 8-K: Biostar Announces Receipt of Nasdaq Continued Listing Deficiency
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, April 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on EX-99.1 2 e]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Resumes Production and Operation at Sinovac Beijing’s Quality Assurance Department The successful resumption of regular production and operations at Sinovac Beijing’s Shangdi manufacturing facility follows the events of April 17, 2018, when Aihua Pan, the Chairman of the Board of Sinovac Bei]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Resumes Production and Operation at Sinovac Beijing’s
[Sinovac Resumes Production and Operation at Sinovac Beijing’s Quality Assurance Department The successful resumption of regular production and operations at Sinovac Beijing’s Shangdi manufacturing facility follows the events of April 17, 2018, when Aihua Pan, the Chairman of the Board of Sinovac Bei]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
